2024 World Conference on Lung Cancer (WCLC) - Posters-P2.05A.02 Incidence of Pneumonitis in Asian Patients with Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis

P2.05A.02 Incidence of Pneumonitis in Asian Patients with Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis

Back to course

Pdf Summary

The systematic literature review and meta-analysis conducted by Christine M. Pierce, PhD, MPH, aims to quantify the incidence of pneumonitis in Asian patients undergoing non-small cell lung cancer (NSCLC) treatments. Pneumonitis, inflammation of lung tissue, is a known adverse event associated with treatments like thoracic radiation and immune checkpoint inhibitors. Recent studies have suggested a higher pneumonitis rate in Asian compared to non-Asian patients, underscoring potential ethnic susceptibility differences.<br /><br />The review involved an extensive search of databases covering English and local Asian languages to identify relevant studies from East and Southeast Asian countries. The review included randomized-controlled trials and non-randomized trials examining pneumonitis risk in patients treated with pharmacological or radiation therapy for NSCLC. Meta-analytical methods were utilized to synthesize data and determine the incidence across different grades of pneumonitis, revealing an all-grade incidence of 5.42%, with lower incidences for more severe grades.<br /><br />Subgroup analysis showed a considerably higher incidence of pneumonitis among patients receiving radiation-based treatments, particularly in grade 1-2 cases. This emphasizes a significantly increased risk associated with radiation-containing regimens. Histological analysis indicated higher pneumonitis incidence in squamous histology compared to non-squamous.<br /><br />The study highlights the treatment-specific risks in Asian populations and is vital for contextualizing safety data from clinical trials involving diverse populations. However, the study did encounter limitations due to the variability in reporting treatment details, pre-existing conditions, and lack of standardization in pneumonitis outcome reporting. These findings could inform clinical strategies and improve patient outcomes by providing a benchmark for interpreting clinical trial results in this demographic. The research acknowledges sponsorship by Merck & Co. and contributions from various researchers affiliated with IQVIA, Inc.

Asset Subtitle

Christine Pierce

Meta Tag

Speaker Christine Pierce

Topic Pulmonology & Staging

Keywords

pneumonitis

non-small cell lung cancer

NSCLC

Asian patients

meta-analysis

radiation therapy

immune checkpoint inhibitors

ethnic susceptibility

squamous histology

clinical trials